ArticleJournal of hepatocellular carcinoma2026
Near-Infrared Fluorescent Probes Targeting LAG-3 for Guiding Immunomodulation and Efficacy Monitoring of Stereotactic Body Radiotherapy in Liver Cancer.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Lymphocyte activation gene 3 (LAG-3) is an attractive biomarker for immunotherapy in hepatocellular carcinoma (HCC) due to its high expression. Based on our previously identified LAG-3 peptide, we developed a LAG-3 targeted peptide probe named Cqy-12-Cy5 for monitoring the dynamic regulation of LAG-3 by stereotactic body radiotherapy (SBRT), thereby providing a strategy to enhance the immunotherapeutic efficacy for HCC. Methods: Immunohistochemistry (IHC) was used to detect the expression of LAG-3 in HCC tissues and its correlation with clinicopathological characteristics. An optical fluorescent probe (Cqy-12-Cy5) was constructed, and its in vivo targeting ability and metabolic profile were evaluated via near-infrared fluorescent (NIRF). Flow cytometry (FCM) was employed to assess the apoptosis of H22 cells after radiation, aiming to screen the optimal radiation dose. Furthermore, the regulatory effect of SBRT on LAG-3 expression in HCC was detected, along with changes in the proportion of CD8 Results: LAG-3 is highly expressed in HCC and is closely related to tumor progression. The fluorescent uptake of the Cqy-12-Cy5 in the tumor region reached a peak at 1 hour after tail vein injection. A radiation dose of 6 Gy was identified as the optimal dose. SBRT could reduce the size of the tumor, promote CD8 Conclusion: The successfully constructed LAG-3-targeting NIRF probe enables non-invasive, real-time monitoring of tumor growth and LAG-3 expression. SBRT can inhibit tumor growth, modulate LAG-3 expression, promote T cell infiltration and cytokine secretion in HCC. The Cqy-12-Cy5 can dynamically monitor the modulation of LAG-3 by SBRT, providing a strategy for guiding the timing of combination therapy and promoting synergistic immunotherapeutic efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.